ABIO ARCA biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABIO

Price (delayed)

$3.65

Market cap

$52.93M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.37

Enterprise value

$15.7M

ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA's lead product candidate, GencaroTM(bucindolol hydrochloride), is an investigational, pharmacologically ...

Highlights
The company's quick ratio has surged by 57% YoY and by 51% QoQ
ARCA biopharma's EPS has increased by 46% YoY
The company's equity fell by 11% YoY and by 2.5% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.arcabiopharma.com
Peers: CYTK PTN MDT UTHR

Key stats

What are the main financial stats of ABIO
Market
Shares outstanding
14.5M
Market cap
$52.93M
Enterprise value
$15.7M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.42
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$5.34M
EBITDA
-$5.23M
Free cash flow
-$5.01M
Per share
EPS
-$0.37
Free cash flow per share
-$0.35
Book value per share
$2.57
Revenue per share
$0
TBVPS
$2.63
Balance sheet
Total assets
$37.86M
Total liabilities
$841,000
Debt
$204,000
Equity
$37.02M
Working capital
$36.96M
Liquidity
Debt to equity
0.01
Current ratio
59.01
Quick ratio
58.76
Net debt/EBITDA
7.12
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-13.3%
Return on equity
-13.8%
Return on invested capital
N/A
Return on capital employed
-14.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABIO stock price

How has the ARCA biopharma stock price performed over time
Intraday
5.8%
1 week
11.62%
1 month
106.21%
1 year
88.14%
YTD
114.71%
QTD
105.06%

Financial performance

How have ARCA biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$7.3M
Net income
-$5.34M
Gross margin
N/A
Net margin
N/A
ARCA biopharma's net income has increased by 46% YoY
ABIO's operating income is up by 31% year-on-year

Growth

What is ARCA biopharma's growth rate over time

Valuation

What is ARCA biopharma stock price valuation
P/E
N/A
P/B
1.42
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ARCA biopharma's EPS has increased by 46% YoY
ABIO's price to book (P/B) is 103% higher than its last 4 quarters average of 0.7 and 78% higher than its 5-year quarterly average of 0.8
The company's equity fell by 11% YoY and by 2.5% QoQ

Efficiency

How efficient is ARCA biopharma business performance
The return on equity has grown by 38% year-on-year
ARCA biopharma's return on assets has increased by 37% YoY

Dividends

What is ABIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABIO.

Financial health

How did ARCA biopharma financials performed over time
The company's quick ratio has surged by 57% YoY and by 51% QoQ
The company's current ratio has surged by 56% YoY and by 50% QoQ
The company's debt is 99% lower than its equity
The company's debt fell by 27% YoY and by 9% QoQ
The company's equity fell by 11% YoY and by 2.5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.